BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Tuesday that the U.S. Food and Drug Administration has approved its albuterol sulfate inhalation aerosol, a generic equivalent ...
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Amneal Pharmaceuticals received Food and Drug Administration approval for its albuterol sulfate inhalation aerosol to treat bronchospasm in people with reversible obstructive airway disease. The ...
Albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults and children 12 years of age and older with reversible obstructive airway disease. Kone ...
Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s albuterol sulfate inhalation aerosol. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback